Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium
NEW YORK and CLEVELAND, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced upcoming oral and poster presentations at the 14th Annual WORLDSymposium(TM) Meeting being held in San Diego, CA, February 5 - 9, 2018.
A phase 1/2 clinical trial of systemic gene transfer of scAAV9.U1a.HSGSH for MPS IIIA: safety, tolerability, and preliminary evidence of biopotency
Presenter: Kevin Flanigan, M.D. - Principal Investigator and Director, Center for Gene Therapy and Neuromuscular Disorders, Nationwide Children's Hospital, Columbus, OH
Date: Thursday, February 8, 2018
Time: 11:00 AM PST
Identification of novel AAV capsids for treatment of lysosomal disorders
Presenter: Daphne Chen, Ph.D., University of North Carolina at Chapel Hill, Chapel Hill, NC
Date: Tuesday, February 6, 2018
Time: 4:00 PM PST
AAV vector comparability across mammalian and insect cell production platforms for treatment of lysosomal diseases
Presenter: Adam S. Davis, Ph.D. - Director of Manufacturing at Abeona Therapeutics
Tuesday, February 6, 2018
Time: 4:30 PM PST
Intravenous administration of CLN3 gene therapy for juvenile neuronal ceroid lipofuscinosis
Presenter: Scott Kerns - Product Development Scientist at Abeona Therapeutics
Tuesday, February 6, 2018
Time: 4:30 PM PST
Poster 329: Combination dosing of CLN1 gene therapy extends lifespan in a mouse model of infantile neuronal ceroid lipofuscinosis
Presenter: Alejandra Rozenberg, Ph.D. - Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Wednesday, February 7, 2018
Time: 4:30 PM PST
About WORLDSymposium(TM): WORLDSymposium is an annual research conference dedicated to lysosomal diseases. W.O.R.L.D. is an acronym that stands for We're Organizing Research on Lysosomal Diseases . Since its inception as a small group of passionate researchers in 2002, WORLDSymposium has grown to an international research conference that attracts over 1600 participants from more than 50 countries around the globe.
About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM(TM), for next generation product candidates. For more information, visit www.abeonatherapeutics.com.
SVP, Head of Investor Relations
Abeona Therapeutics Inc.
+1 (646) 813-4707
Berry & Company Public Relations
+1 (212) 253-8881
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals and licenses; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abeona Therapeutics Inc via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Nasdaq Welcomes Dropbox, Inc. (Nasdaq: DBX) to The Nasdaq Stock Market23.3.2018 19:52 | Pressmeddelande
NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- Dropbox, Inc. (Nasdaq:DBX), a leading global collaboration platform, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market. Founded in 2007, Dropbox serves more than 500 million registered users across 180 countries. Over the past decade, Dropbox has pioneered the worldwide adoption of file sync and share software and has expanded its product capabilities to help users do their best work. Today, 80% of its 11 million paying customers use Dropbox for work. "Today we're taking an important step in our journey. I'm so grateful to all of our customers and our incredible team for getting us here," said Drew Houston, Co-Founder and Chief Executive Officer. "Nasdaq has always championed innovation and entrepreneurship, and we're thrilled to partner with them as we become a public company." "For more than a decade, Dropbox has transformed how people around the world access
Barings Alternative Investments Expands Aviation Investment Platform Through Partnership with Genesis Aircraft Services23.3.2018 15:00 | Pressmeddelande
CHARLOTTE, N.C., March 23, 2018 (GLOBE NEWSWIRE) -- Barings Alternative Investments, part of Barings LLC, one of the world's leading financial services firms, announced today the expansion of its aircraft leasing platform on behalf of the firm's institutional fund clients through Genesis Aircraft Services Limited. To facilitate new aircraft acquisitions on behalf of Barings' clients, Genesis will increase existing capabilities to now include all commercial, technical, portfolio and legal management functions required of a full-service premier owner and lessor of commercial aircraft. As part of its increased capabilities, Karl Griffin will join Genesis as Chief Commercial & Investment Officer and will also be appointed to the Genesis Board of Directors effective May 2018; Anna Reimers will join Genesis as Chief Legal Officer; and John McMahon will be appointed to Genesis' Board as an independent director. Griffin is currently the Chief Operating Officer at DAE Capital, an aircraft leasi
Agrisolutions Acquires Trinity23.3.2018 12:00 | Pressmeddelande
HAMILTON, Ontario, March 23, 2018 (GLOBE NEWSWIRE) -- Venanpri Group's Agrisolutions division, which services the global agricultural marketplace with its Ingersoll and Bellota brands, announced today the acquisition of Trinity Logistics Corporation ("Trinity"). Based in the U.S., Trinity provides supply-chain solutions relating to fasteners and other components to leading global OEMs that produce mission critical machinery for the agricultural and construction end markets. The terms of the transaction were not disclosed. Headquartered in Davenport, Iowa, Trinity has established ten strategically located service facilities throughout the United States. Trinity specializes in the supply of standard and custom components through vendor managed inventory programs and other arrangements tailored to customer needs. Trinity utilizes its industry leading technology to improve the flow of products, services and information across the supply chain resulting in excellence in the operations of it
BIMobject AB: BIMobject releases toolkit to help digitalise the construction industry23.3.2018 10:57 | Pressmeddelande
BIMobject releases a toolkit for easy, seamless integration of BIM-softwares with the corporation's cloud-based platform, which hosts digital building products. This gives building product manufacturers more marketing channels and easier access to the platform's user base. BIMobject's new Software Development Kit (SDK) is a quick, efficient way for third party-developers to start using the BIMobject platform. It allows for BIMobject's market-leading platform for digital building products easily to be integrated in different BIM-programmes, such as apps. The design, user experience, and features can be defined entirely by the developer. The SDK is made available as an open source-code for free download and is connected to the web interface upon application. The code is freestanding, making it independent of updates. This in turn makes the SDK future-proof, easy to apply, and less vulnerable, with reduced loading time of the integrated digital content. For more information, please contac
BIMobject AB: BIMobject släpper startkit som hjälper byggbranschen att digitaliseras23.3.2018 10:57 | Pressmeddelande
BIMobject släpper ett startkit som gör det enkelt att skapa sömlös integration av BIM-programvaror med bolagets molnbaserade plattform BIMobject Cloud för digitala byggprodukter. Produkttillverkare ges på så vis fler marknadsföringskanaler och smidigare tillgång till plattformens användarbas. BIMobjects nya Software Development Kit (SDK) gör det enkelt för tredjepartsutvecklare att snabbt börja använda bolagets webbgränssnitt. Innehållet som tillhandahålls på BIMobjects marknadsledande plattform för digitala byggprodukter kan på så vis enkelt integreras i olika BIM-program, exempelvis i form av appar. Design, användarupplevelse och funktioner kan bestämmas helt av utvecklaren. Startkitet tillhandahålls som öppen källkod ("open-source") för gratis nedladdning och kopplas till webbgränssnittet efter ansökan. Koden i startkitet är fristående och därför oberoende av uppdateringar. Detta gör startkitet framtidssäkert, lättapplicerat, mindre sårbart och kortar dessutom ned laddningstider av
Comodo CA Sees 35 Percent Year-Over-Year Increase in EV Certificates22.3.2018 15:47 | Pressmeddelande
EV SSL will be a topic of discussion at the Comodo CA booth during RSA 2018 CLIFTON, N.J., March 22, 2018 (GLOBE NEWSWIRE) -- Comodo CA, a worldwide leader in digital identity solutions, will address evolving cyberthreats and the increasing importance Extended Validation (EV) TLS/SSL certificates play in securing websites and inspiring consumer trust at the RSA Conference 2018, San Francisco, April 16 - 20. According to the Feb 2018 Netcraft report, Comodo CA has seen a 35 percent year-over-year increase of EV certificate units* making it one of the fastest growing providers of high assurance certificates. The volume of EV certificates globally also saw a record year in 2017 as more and more businesses adopt EV as standard practice for their websites. The demand for stronger, more secure EV certificates comes in the wake of increased phishing websites using Domain Validated (DV) certificates. Phishing websites imitate legitimate websites to steal customers' funds and identities. Phishi
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum